Why the study?
To explore concepts of emerging anti-cancer therapies and their plausible cardiotoxic effects, describe knowledge gaps, and discuss reverse cardio-oncology and translational research.
Key points are not available for this paper at this time.
Design
Review article
Supports awareness of emerging toxicities and bidirectional risk without altering practice; leaves open trials of reverse cardio-oncology.
Cardio-oncology was established with the aim of defining primary and secondary prevention approaches through surveillance and the use of tools to stratify and diminish the cardiovascular risk to cancer patients. This branch of medicine also contributes to establishing a new field in translational medicine for cardiovascular disease by focusing on the interplay between cancer and heart disease. In this first article in the new cardio-oncology section of the journal, we explore the main concepts of emerging anti-cancer therapies and their plausible cardiotoxic effects and we will describe advances and gaps in knowledge, highlighting how cardio-oncology is contributing to translational cardiology. We will speculate on the complex interplay between cancer and heart failure and discuss an emerging concept known as reverse cardio-oncology. We also present the perspective that cardio-oncology represents a promising platform area of research, allowing the discovery of novel pathways involved in cardiovascular disease through the identification of toxicities induced by targeted cancer therapies.
No takes yet. Share an insight, caveat, or question.
Camilli et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: